Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions
Journal of Clinical Medicine · 03.10.2025 · 14 (19) · 7009
DOI: 10.3390/jcm14197009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.10.2025. Verfasst von Ximena Parraga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of cancer death, with liver transplantation (LT) offering a curative option for early-stage patients who cannot undergo resection. Although LT provides good long-term outcomes within standard criteria, recurrence occurs in approximately 8–20% of recipients and often leads to poor survival. Traditionally, LT eligibility relied on strict criteria like the Milan criteria, which are effective in selecting patients with low recurrence but may exclude patients who could benefit from transplantation. In response, new expanded criteria and models using tumor biology have been developed for better risk stratification, allowing more personalized selection and management. Despite these advances, recurrence remains a major clinical challenge, with no consensus on optimal imaging timing or frequency post-LT. Treatment depends on the recurrence’s extent and location, including surgical resection and locoregional therapies. Systemic treatments are promising, especially for unresectable or extrahepatic recurrence, though most evidence comes from small retrospective studies, limiting the development of standardized protocols. Future research should focus on addressing these gaps and guiding evidence-based post-transplant care. This is a narrative review summarizing recent advances in HCC recurrence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
- Division of Transplantation, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
- Division of Internal Medicine, Saint Peter's University Hospital, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
ORCID-Profile: Ximena Parraga, Eyad Abdulrazzak, Ritah R Chumdermpadetsuk, Marwan Alsaqa, Shanmukh Pavan Lingamsetty, Alan Bonder, Behnam Saberi
Zitieren
APA
Parraga, X., Abdulrazzak, E., Chumdermpadetsuk, R. R., Alsaqa, M., Pavan Lingamsetty, S., Bonder, A., & Saberi, B. (2025). Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions. Journal of Clinical Medicine, 14(19), 7009. https://doi.org/10.3390/jcm14197009
Vancouver
Parraga X, Abdulrazzak E, Chumdermpadetsuk RR, Alsaqa M, Pavan Lingamsetty S, Bonder A, et al. Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions. Journal of Clinical Medicine. 2025;14(19):7009. doi:10.3390/jcm14197009
BibTeX
@article{Parraga2025,
author = {Parraga, Ximena and Abdulrazzak, Eyad and Chumdermpadetsuk, Ritah R and Alsaqa, Marwan and Pavan Lingamsetty, Shanmukh and Bonder, Alan and Saberi, Behnam},
title = {Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {19},
pages = {7009},
doi = {10.3390/jcm14197009}
}
EUVIMED